Background
==========

Mild traumatic brain injury (MTBI) affects approximately 42 million people worldwide \[[@b1-medscimonit-23-6099]\], and it is thought that these injuries induce neurobehavioral changes in patients \[[@b2-medscimonit-23-6099]\]. MTBI may also result in the development of neurodegenerative diseases such as cognitive dysfunction, amyotrophic lateral sclerosis (ALS), Parkinson disease, and Alzheimer disease \[[@b3-medscimonit-23-6099]\]. Additionally, mechanical injury can initially induce MTBI and subsequently cause secondary injuries as the disease progresses \[[@b4-medscimonit-23-6099]\]. The literature suggests that neuro-inflammation and increased levels of oxidative stress are responsible for the progression of the neurodegeneration associated with MTBI \[[@b5-medscimonit-23-6099]--[@b7-medscimonit-23-6099]\].

Neuro-inflammation is the result of immune reactions occurring in the brain that enhance glutamate levels and increase the production of reactive oxygen species (ROS), which, in turn, promote inflammatory reactions \[[@b8-medscimonit-23-6099]\]. Moreover, glial scars may form due to neuro-inflammation, which may prevent neuronal regeneration and impair cognitive function \[[@b9-medscimonit-23-6099]\]. Although the limited number of drugs available for the treatment of MTBI can effectively manage its symptoms, this disorder significantly enhances the risk of cognitive dysfunction \[[@b10-medscimonit-23-6099]\]. Traditional Chinese medicines and compounds derived from them have been used to effectively manage MTBI \[[@b11-medscimonit-23-6099],[@b12-medscimonit-23-6099]\]. For example, *Malva sylvestris* L. (MS) of the Malvaceae family, which is traditionally used as medicine in China, reportedly exerts anti-inflammatory, antioxidant, bacteriostatic, anti-nociceptive, and anticholinesterase activities \[[@b13-medscimonit-23-6099]--[@b15-medscimonit-23-6099]\]. Phytochemical investigations have revealed that MS herbs contain several biologically active chemical components that include essential oils, sesquiterpenes, leucoanthocyanidins, anthocyanins, coumarins, and anthocyanins \[[@b13-medscimonit-23-6099]\]. Coumarins and anthocyanins are known to protect against neurodegeneration in cases of cerebral ischemia \[[@b16-medscimonit-23-6099],[@b17-medscimonit-23-6099]\]. Thus, the present study evaluated the effects of MS on cognitive deficits induced in a repetitive MTBI rat model.

Material and Methods
====================

Animals
-------

Sprague-Dawley rats of 200 g to 250 g body weight were used in this study. All the rats were housed under a controlled condition specified as per guidelines. All the experiments used in this study are approved by the Animal Ethical Committee of the Southern Medical University, China (IEC/SMU/2016/19); this study followed the guidelines of Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) for experimentation and animal use.

Preparation of extract
----------------------

Whole plants of *Malva sylvestris* (MS) were collected and authenticated from the Botanical Department of the Southern Medical University, China. Whole plants were air dried after washing. Dried plants were cut into small pieces and coarsely ground into powder using a grinder. The powder was kept in 95% methanol in a bottle for seven day for maceration. The extract was filtered out and the filtrate was dried using a rotary evaporator. The practical yield of the extract was found to be 16.5% w/w.

Induction of MTBI
-----------------

MTBI was induced as per previously reported methods by hitting a metallic pendulum near the parietal-occipital area of the skull three times a day for ten days. The following formula was used to assess the severity of injury: record the timing of recovery of physiological parameter instantly after the injury and score it accordingly as apnea (xp1), external auditory meatus reflex (xp2), righting reflex response (xp3), corneal reflex (xp4), or response to painful stimulus (xp5). Then according to the formula Y=0.133x~p1~+0.264x~p2~+0.027x~p3~+ 0.196x~p4~--0.006x~p5~--2.982, if Y \<0.319 and injured rat with apnea, then the rat was defined as MTBI. All the animals defined as MTBI were selected for further study.

Treatment protocol
------------------

All the MTBI animals were separated into four groups: control group received solvent only, negative control group received no treatment, and MS treated groups received the extract (250 mg/kg or 500 mg/kg) intragastrically per day for the duration of seven consecutive days.

Assessment of cognitive function by Morris water maze
-----------------------------------------------------

Cognitive function was tested by Morris water maze (MWM) method by having a tank dimension of 180 cm diameter and 70 cm height. The tank was separated into four quadrants with suitable labeling and the stage kept 2 cm below the water level. All rats were trained for five days, two sessions a day, at an interval of two hours after the production of injury. There were four trials in each session, performed at an interval of 30 seconds. In each trial, the rat was placed in a quadrant and permitted to search for the stage. If the rat was not able to locate the stage in two minutes then the rat was placed on the stage for two minutes for consideration of the escape latency. Spatial memory of the trained rats were investigated by removing the stage from the quadrant and estimating the duration of time spent by a rat in a specified quadrant at the end of the protocol. All the MWM trials were performed at a specific time of the day to avoid time of day related variation in performance.

Tissue preparation
------------------

At the end of protocol, all the animals were injected with 10% chloral hydrate intraperitoneally to produce anesthesia. The brain was isolated from each animal and fix in 4% paraformaldehyde. Then the brain was stored at 4°C in a 30% sucrose solution. The isolated brain was separated into two sections. One section of the brain was used for anti GFAP staining and Nissl staining. The other section of the brain of each rat was homogenized instantaneously in a solution containing Tris-HCl (50 mM, pH 7.4) and sucrose (300 mM). The homogenate was centrifuged at 10,000 g for the duration of 10 minutes, and the supernatant was separated for biochemical estimation.

Nissl staining
--------------

Isolated rat brain sections were placed into 4% paraformaldehyde for one day and dehydrated with alcohol. Dehydrated sections were dipped into paraffin and then using a microtome, sliced into 5 μm tissue sections. The tissue slices were stained with Nissl staining in 1% thionin. Neuronal cells counting was done using a light microscope (400x) focused on the hippocampus areas Ca1, Ca3, and DG.

Anti GFAP staining
------------------

The isolated brain was cut into sections using a microtome. Tissue sections were kept under citric acid buffer solution for 45 minutes to estimate antigens, and PBS was used to rehydrate the tissue sections for 10 minutes for the estimation of astrocytosis. Later, permeabilization buffer (PBS containing 0.1% Triton X and 4% goat serum) was used for 60 minutes to permeabilized the tissue block sections. GFAP specific monoclonal primary antibody (1: 400, MAB360) was incubated with the tissue sections at 4°C overnight. Thereafter, on the next day, biotin-conjugated secondary antibody was incubated with tissue sections at room temperature for two hours. Tissues were further treated with streptavidin-peroxidase for 12 minutes after washing with 1% Triton X and 0.01 M PBS solution. Moreover, tissue sections were treated with developing agent diaminobenzidine for 10 minutes; thereafter tissue sections were dehydrated by adding alcohol (95%) twice, and tissues were mounted on the slides using neutral gum solution. The hippocampus area of the brain (Ca1, Ca3, and DG) was photographed by using trinocular microscope at 400×.

Estimation of ROS generation
----------------------------

The estimation of the production of ROS was done as per He et al. Tissue homogenates were kept for the estimation of intensity of fluorescence at wavelength of 488 nm for excitation and 530 nm for emission using flow cytometer. Moreover, swelling of the mitochondria was determined by estimating the optical density at a wavelength of 520 nm as per a previous study. The degree of swelling of the mitochondria was reflected by the turbidity of reactant product.

Estimation of markers of oxidative stress
-----------------------------------------

Superoxide dismutase (SOD) was estimated in the brain tissue of rats by using the riboflavin sensitized method; the alteration in absorbance was observed for four minutes at 460 nm.

The level of lipid peroxidation (LPO) was estimated (using the Ohkawa method) in the tissue homogenate; the amount of malondialdehyde (MDA) was estimated at 532 nm.

The activity of catalase (CAT) in the brain tissue was assessed based on the ability to catalase to oxidize H~2~O~2~. The alteration in the level of absorbance was estimated for three minutes at one minute intervals at 240 nm.

Estimation of cytokines
-----------------------

The level of cytokines, such as IL1β, IL6, and TNFα, were estimated in the tissue homogenate by using specific enzyme-linked immunosorbent assay (ELISA) kits as per the instruction given in the individual kits.

Statistical analysis
--------------------

Data is represented as mean ±SD (n=10). All the results were analyzed statistically by one way ANOVA and post hoc study by Dunnett. In this study, values of *p*\<0.05 was considered as significant.

Results
=======

Effect of MS on cognitive function
----------------------------------

The effect of MS on cognitive function in the repetitive MTBI in rats using MWM apparatus is shown in [Figure 1](#f1-medscimonit-23-6099){ref-type="fig"}. There were significant (*p*\<0.01) increases in the escape latency in the negative control group (no treatment) compared to the control group (solvent-only). However, treatment with MS significantly decreased the escape latency compared to the negative control group in the MTBI rat model ([Figure 1A](#f1-medscimonit-23-6099){ref-type="fig"}). The time spend in the target quadrant significantly decreased (*p*\<0.01) in MTBI rats compared to the control group, and MS treated group showed significant reduction in the time spend in the target quadrant compared to the negative control group ([Figure 1B](#f1-medscimonit-23-6099){ref-type="fig"}).

Effect of MS on neurodegeneration
---------------------------------

Nissl staining was done to estimate the neurodegeneration on the hippocampus of the repetitive MTBI rats as shown in [Figure 2](#f2-medscimonit-23-6099){ref-type="fig"}. It was observed that the degeneration of neuron was significantly enhanced in the MTBI rats compared to the control rats (*p*\<0.01). However treatment with MS 250 mg/kg and MS 500 mg/kg significantly decreased the count of neurodegeneration in Ca1 and Ca3 regions of hippocampus of the MTBI rats compared to the negative control rats (*p*\<0.01).

Effect of MS on the astrocytosis induction
------------------------------------------

Anti GFAP staining was done to estimate the effect of MS on astrocytosis induced by MTBI in the hippocampus of the rats as shown in [Figure 3](#f3-medscimonit-23-6099){ref-type="fig"}. There was a significant increase in the count of GFAP positive cells in the hippocampal region Ca1 and Ca3 of the negative control rats. It was observed that treatment with MS at 250 mg/kg and 500 mg/kg significantly decreased the enhanced count of GFAP positive cells in the hippocampal region Ca1 and Ca3 of MTBI rats compared to the negative control rats.

Effect of MS on the production of ROS and oxidative stress parameters
---------------------------------------------------------------------

The effect of MS on the production of ROS and oxidative stress parameters in repetitive MTBI rats are shown in [Figure 4](#f4-medscimonit-23-6099){ref-type="fig"} and [Table 1](#t1-medscimonit-23-6099){ref-type="table"}. It was observed that the production of ROS in brain tissue of MTBI rats was significantly enhanced compared to control rats. However, the quantity of ROS production significantly decreased in the MS treated groups compared to the negative control group.

Oxidative stress parameters, such as SOD, LPO, and CAT, also get altered in MTBI rats. The activity of SOD significantly decreased while CAT and LPO activity was significantly enhanced in the brain tissue of the MTBI rats compared to the control rats. These altered activities of SOD, CAT, and LPO were found to be significantly attenuated in the MS treated rats compared to the negative control rats.

Effect of MS on inflammatory cytokines
--------------------------------------

The effect of MS on the concentration of inflammatory cytokines, such as IL1β, IL6, and TNFα, in the brain tissues of the MTBI rats is shown in [Figure 5](#f5-medscimonit-23-6099){ref-type="fig"}. There were significant increases in the concentration of IL1β, IL6, and TNFα in the brain tissue of the MTBI rats (negative control group) compared to the control rats. Treatment with MS 250 mg/kg and MS 500 mg/kg significantly decreased the concentration of IL1β, IL6, and TNFα in the brain tissues of the MTBI rats compared to the negative control rats in a dose dependent manner.

Discussion
==========

MTBI affected patients suffer from neurodegenerative disorders and there are a limited number of drugs available for the management of these neurodegenerative disorders. In the recent era, scientists have focused on alternative therapies for the management of cognitive dysfunction induced by MTBI. Thus, this report evaluated the effect of MS on cognitive deficits in a MTBI rat model.

The literature suggests that MTBI alters cognitive functions by enhancing neurodegeneration \[[@b11-medscimonit-23-6099]\]. The results of our study suggested that the time spent in the target quadrant and the escape latency were significantly decreased in MTBI rats compared to the control group. However, treatment with MS significantly attenuated the cognitive function by improving the time spent in the target quadrant and the escape latency in the MTBI rats. Cognitive defects due to neurodegeneration and the drugs that protect neurodegeneration seem to attenuate the cognitive defect in MTBI rats \[[@b18-medscimonit-23-6099]\]. Our study results suggested that treatment with MS significantly decreased the neurodegeneration count and MTBI-induced astrocytosis in the brain tissue of MTBI rats.

The literature has reported that in MTBI, enhanced oxidative stress results in neurodegeneration, and antioxidant drugs effectively reduce/prevent neurodegeneration by decreasing oxidative stress \[[@b19-medscimonit-23-6099],[@b20-medscimonit-23-6099]\]. In a MTBI rat model, by reducing oxidative stress and the generation of free radicals, drugs improve cognitive functions and reduce neuronal death \[[@b21-medscimonit-23-6099]\]. Our study also found that treatment with MS 250 mg/kg and MS 500 mg/kg significantly decreased the concentration of ROS and the activity of LPO, and increased the activity of SOD and CAT enzymes in the brain tissues of MTBI rats.

MTBI-induced cognitive dysfunction occurs due to neuro-inflammation, and the induction of astrocytosis plays a vital role in neuro-inflammation \[[@b22-medscimonit-23-6099]--[@b24-medscimonit-23-6099]\]. MS is reported to possess strong anti-inflammatory activity and anti-cholinesterase activity. The result of our study showed that treatment with MS 250 mg/kg and MS 500 mg/kg significantly reduced the concentration of IL1β, IL6, and TNFα in the brain tissue of MTBI rats. Moreover, the histopathology of the MS treated group suggested that induction of astrocytosis was significantly reduced by the decreasing number of GFAP positive cells and thereby improved cognitive function. Thus, MS effectively attenuated the cognitive function in MTBI rats by decreasing neuro-inflammation concentrations in the brain tissues.

Conclusions
===========

This study concluded that treatment with MS significantly improved cognitive dysfunction by reducing neurodegeneration and astrocytosis in brain tissues via decreasing oxidative stress and inflammation in neuronal cells.
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![Effect of *Malva sylvestris* on cognitive function in the repetitive mild traumatic brain injury rat model: (**A**) escape latency; (**B**) time spent in the target quadrant. Values are means ±SD; \*\* *p*\<0.01 compared to the control group, ^\#\#^ *p*\<0.01 compared to the negative control group.](medscimonit-23-6099-g001){#f1-medscimonit-23-6099}
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![Effect of *Malva sylvestris* on the astrocytosis induced by repetitive mild traumatic brain injury in rat hippocampus: (**A**) anti GFAP staining; (**B**) the count of GFAP positive cells. Values are means ±SD; \*\* *p*\<0.01 compared to the control group, ^\#\#^ *p*\<0.01 compared to the negative control group.](medscimonit-23-6099-g003){#f3-medscimonit-23-6099}
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![Effect of *Malva sylvestris* on the concentration of inflammatory cytokines in repetitive mild traumatic brain injured rats. Values are means ±SD; \*\* *p*\<0.01 compared to the control group, ^\#\#^ *p*\<0.01 compared to the negative control group.](medscimonit-23-6099-g005){#f5-medscimonit-23-6099}

###### 

Effect of *Malva sylvestris* on SOD, LPO & CAT in the brain tissue of repetitive mild traumatic brain injured rat.

  Sr. No.   Group              SOD (Unit/mg protein)                                            LPO (nmol MDA/mg protein)                                        CAT (μmol H~2~O~2~ consumed/min/mg protein)
  --------- ------------------ ---------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  1         Control            14.2±1.2                                                         7.9±0.5                                                          49.1±2.1
  2         Negative control   3.8±0.4[\*\*](#tfn2-medscimonit-23-6099){ref-type="table-fn"}    15.1±1.3[\*\*](#tfn2-medscimonit-23-6099){ref-type="table-fn"}   72.5±5.5[\*\*](#tfn2-medscimonit-23-6099){ref-type="table-fn"}
  3         MS 250 mg/kg       10.2±1.1[\#\#](#tfn3-medscimonit-23-6099){ref-type="table-fn"}   10.3±0.6[\#\#](#tfn3-medscimonit-23-6099){ref-type="table-fn"}   60.3±3.2[\#\#](#tfn3-medscimonit-23-6099){ref-type="table-fn"}
  4         MS 500 mg/kg       13.1±1.3[\#\#](#tfn3-medscimonit-23-6099){ref-type="table-fn"}   8.3±0.3[\#\#](#tfn3-medscimonit-23-6099){ref-type="table-fn"}    53.9±2.4[\#\#](#tfn3-medscimonit-23-6099){ref-type="table-fn"}

Values are means ±SD;

p\<0.01 than Control group,

p\<0.01 than Negative control group.
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